Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Stem Cell Therapy for Tissue Regeneration

Stem Cell Therapy for Tissue Regeneration

Stem cell therapy is a method used in regenerative medicine to repair and restore function to damaged tissues and organs. Stem cells have the potential to proliferate and differentiate into various tissue types, making them ideal candidates for tissue regeneration. For example, hematopoietic stem cell transplants are commonly used in blood cancer treatment to replenish damaged bone marrow and restore healthy blood cells.
Types of Stem Cells used in Stem Cell Therapy
The two main cell...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Targeted Cancer Therapies

Targeted Cancer Therapies

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma Virus (RSV) and Cancer

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Case Report: Bilateral optic nerve head masses and retinopathy in a patient with B-cell acute lymphoblastic leukemia receiving CAR T-cell therapy masquerading as fungal endophthalmitis.

Frontiers in immunology·2026

Same author

Donor lymphocyte infusions after HCT are associated with low risk of graft-versus-host disease in pediatric and young adult patients.

Blood immunology & cellular therapy·2026

Same author

Costimulation drives CAR-T cell division fate.

Nature immunology·2026

Same author

Successful autologous T cell apheresis in pediatric patients with hematologic malignancies, solid tumors, and brain tumors.

Cytotherapy·2026

Same author

Adoptive T-Cell Immunotherapy.

Current topics in microbiology and immunology·2026

Same author

Biomarkers for Diagnosis, Risk Stratification, and Immunotherapy of Pediatric Solid Tumors.

American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting·2026

Same journal

Utility of serum Krebs von den Lungen-6 and surfactant protein D levels for differential diagnosis of immune checkpoint inhibitor-related pneumonitis.

Immunotherapy·2026

Same journal

Anti-PD-(L)1 plus chemotherapy in advanced PD-L1-negative nonsquamous non-small cell lung cancer: a systematic review and meta-analysis.

Immunotherapy·2026

Same journal

Anti-TIGIT therapies in digestive cancers: from immune evasion to precision immunotherapy.

Immunotherapy·2026

Same journal

CAR cellular therapies for acute myeloid leukemia: current landscape and future directions.

Immunotherapy·2026

Same journal

Recent advances in bispecific natural killer cell engagers for cancer immunotherapy.

Immunotherapy·2026

Same journal

Exploring global research trends in sublingual immunotherapy of allergic rhinitis: a comprehensive bibliometric analysis.

Immunotherapy·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Apr 18, 2026

The In ovo CAM-assay as a Xenograft Model for Sarcoma

The In ovo CAM-assay as a Xenograft Model for Sarcoma

Published on: July 17, 2013

Adoptive cell therapy for sarcoma.

Melinda Mata¹, Stephen Gottschalk

¹Center for Cell & Gene Therapy, Texas Children's Hospital, Houston Methodist Hospital, Baylor College of Medicine, 1102 Bates Street, Suite 1770, Houston, TX 77030, USA.

|January 10, 2015

Summary

This summary is machine-generated.

Novel cell therapies offer new hope for treating recurrent or metastatic sarcomas, moving beyond traditional treatments. This review explores genetically enhanced cell therapies to improve effectiveness against solid tumors.

Keywords:

cancer immunotherapy cell therapy gene transfer sarcoma

More Related Videos

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

Isolation and Characterization of Tumor-initiating Cells from Sarcoma Patient-derived Xenografts

Isolation and Characterization of Tumor-initiating Cells from Sarcoma Patient-derived Xenografts

Published on: June 13, 2019

Related Experiment Videos

Last Updated: Apr 18, 2026

The In ovo CAM-assay as a Xenograft Model for Sarcoma

The In ovo CAM-assay as a Xenograft Model for Sarcoma

Published on: July 17, 2013

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

Isolation and Characterization of Tumor-initiating Cells from Sarcoma Patient-derived Xenografts

Isolation and Characterization of Tumor-initiating Cells from Sarcoma Patient-derived Xenografts

Published on: June 13, 2019

Area of Science:

Oncology
Immunotherapy
Cellular Therapy

Background:

Current sarcoma therapies are limited for recurrent or metastatic disease.
Novel treatment strategies are crucial for improving patient outcomes.
Cell therapy presents a promising alternative to conventional cytotoxic treatments.

Purpose of the Study:

To review current cell therapy approaches for sarcoma.
To highlight the potential of cell therapy in treating solid tumors.
To emphasize genetic modifications for enhancing adoptively transferred cell function.

Main Methods:

Literature review of current cell therapies for sarcoma.
Focus on T-cell therapies and their application to solid tumors.
Discussion of genetic engineering techniques to improve effector functions.

Main Results:

Cellular therapies show potential for overcoming limitations of conventional sarcoma treatments.
Genetic modification strategies can enhance the efficacy of adoptively transferred cells.
Recent successes in hematological malignancies inspire exploration in solid tumors.

Conclusions:

Cell therapy, particularly with genetic enhancements, is a promising avenue for advanced sarcoma treatment.
Further research into genetically modified cell therapies is warranted for sarcomas.
This approach may offer a new paradigm for managing recurrent and metastatic sarcoma.